^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Retacrit (epoetin alfa-epbx)
i
Other names: SB-309, SB 309, SB309
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Norbitec, Pfizer, Stada
Drug class:
Erythropoiesis stimulating agent
Related drugs:
1year
NCI-2009-01173: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (clinicaltrials.gov)
P3, N=247, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Oct 2025
Trial completion date • Combination therapy
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CDC25C (Cell Division Cycle 25C) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
|
lenalidomide • Retacrit (epoetin alfa-epbx)
over2years
NCI-2009-01173: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (clinicaltrials.gov)
P3, N=247, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2023 --> Sep 2024
Trial completion date • Combination therapy
|
lenalidomide • Retacrit (epoetin alfa-epbx)
Share via
